Current Developments in the Preclinical and Clinical use of Natural Killer T cells.
Christina KratzmeierSasha SinghEmmanuel B AsieduTonya J WebbPublished in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2022)
Natural killer T (NKT) cells play a pivotal role as a bridge between the innate and the adaptive immune response and are instrumental in the regulation of homeostasis. In this review, we discuss the potential for NKT cells to serve as biodrugs in viral infections and in cancer. NKT cells are being investigated for their use as a prognostic biomarker, an immune adjuvant, and as a form of cellular therapy. Historically, the clinical utility of NKT cells was hampered by their low frequency in the blood, discrepancies in nomenclature, and challenges with ex vivo expansion. However, recent advances in the field have permitted the development of several NKT cell-based preclinical and clinical strategies. These new developments pave the way for the successful implementation of NKT cell-based approaches for the treatment of human disease.
Keyphrases
- induced apoptosis
- immune response
- cell cycle arrest
- cell therapy
- primary care
- endothelial cells
- healthcare
- signaling pathway
- oxidative stress
- stem cells
- squamous cell carcinoma
- cell death
- mesenchymal stem cells
- quality improvement
- mass spectrometry
- pi k akt
- climate change
- atomic force microscopy
- single molecule
- dendritic cells
- papillary thyroid
- combination therapy